2022
Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer
Leone JP, Hassett MJ, Leone J, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Lin NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer 2022, 128: 3796-3803. PMID: 36069365, PMCID: PMC9826058, DOI: 10.1002/cncr.34448.Peer-Reviewed Original ResearchConceptsPathologic complete responseFive-year OSNeoadjuvant chemotherapyMale breast cancerBreast cancerTumor subtypesOverall survivalIndependent associationEfficacy of NACInitiation of NACHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2National Cancer DatabaseGrowth factor receptor 2Multivariable logistic regressionFemale breast cancerFactor receptor 2HR-/HER2Complete responseMedian timeMultivariable analysisKaplan-MeierCancer DatabaseReceptor 2Logistic regression
2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19
Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo A, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. The Oncologist 2021, 26: 685-693. PMID: 33856099, PMCID: PMC8251362, DOI: 10.1002/onco.13794.Peer-Reviewed Original ResearchConceptsHistory of cancerIndependent risk factorDeath/hospiceSevere COVID-19Survivors of cancerHospitalized patientsCancer historyActive cancerRisk factorsCurrent cancer diagnosisCancer diagnosisCOVID-19Laboratory-confirmed COVID-19Intensive care unit admissionCare unit admissionOdds of intubationCancer-directed therapySystemic cancer therapyStandard anticancer therapiesRecent cancer treatmentUnit admissionHospice admissionMedian ageMedian timeMultivariable analysis
2020
53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnack A, DiGiovanna M, Bachelot T, Chien A, O’Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An X, Winer E. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). Neuro-Oncology Advances 2020, 2: ii11-ii11. PMCID: PMC7401403, DOI: 10.1093/noajnl/vdaa073.041.Peer-Reviewed Original ResearchMetastatic breast cancerBrain metastasesCNS-PFSSecond progressionControl armEfficacy analysisBrain progressionExploratory efficacy analysesMedian CNS-PFSBaseline brain MRIMedian OSOverall deathRECIST 1.1Study therapyMedian timeInvestigator's evaluationIC diseaseLocal treatmentBreast cancerBrain MRIReduced riskCapecitabineTrastuzumabTucatinibHER2Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.
Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of Clinical Oncology 2020, 38: 587-587. DOI: 10.1200/jco.2020.38.15_suppl.587.Peer-Reviewed Original ResearchFemale breast cancerPathologic complete responseNeoadjuvant chemotherapyOverall survivalClinical responseTumor subtypesBreast cancerWorse OSExact testHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusEfficacy of NACInitiation of NACNational Cancer Database studyComplete clinical responseHormone receptor statusMale breast cancerLog-rank testFisher's exact testHR-/HER2Complete responseMedian ageReceptor statusMedian timeClinical stage
2019
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3: 1-9. PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/po.19.00087.Peer-Reviewed Original ResearchMetastatic breast cancerEligible patientsBreast cancerExact testHER2-negative breast cancerOngoing phase II trialGenomic profilingPhase II trialProportion of patientsComprehensive genomic profilingRoutine clinical practiceFisher's exact testGenomic tumor profilingArchived tissue samplesII trialMedian timeTRIAL REGISTRATIONTrial participationClinical trialsSpecific genomic changesClinical impactGenomic testing resultsRare subsetPatientsClinical practiceIMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).
Schneeweiss A, Rugo H, Winer E, Barrios C, Iwata H, Dieras V, Loi S, Maiya V, Bond J, Lei G, Chui S, Adams S, Emens L, Schmid P. IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). Journal Of Clinical Oncology 2019, 37: 1068-1068. DOI: 10.1200/jco.2019.37.15_suppl.1068.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerTriple-negative breast cancerTolerable safety profileCauses of withdrawalMonotherapy trialsPFS benefitSerious AEsSystemic corticosteroidsMedian FUSecondary endpointsNab-paclitaxelAdverse eventsPD-L1Peripheral neuropathyMedian timeSafety profileLonger FUSafety signalsBreast cancerSafety dataCumulative toxicityData cutAESIP3 studiesGr 3
2016
The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research.
Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. Journal Of Clinical Oncology 2016, 34: lba1519-lba1519. DOI: 10.1200/jco.2016.34.18_suppl.lba1519.Peer-Reviewed Original ResearchMetastatic breast cancerBreast Cancer ProjectMedical recordsMedian timeBreast cancerDe novo metastatic breast cancerMedical providersCancer ProjectNovo metastatic breast cancerMedian ageInitial diagnosisTumor biopsiesMost tumorsSaliva kitsClinical informationNationwide studyExtraordinary responsePatient approachCommunity settingsTumorsPatient initiativeSaliva samplesTherapyGermline DNACancerRandomized trial of a physical activity intervention in women with metastatic breast cancer
Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer 2016, 122: 1169-1177. PMID: 26872302, DOI: 10.1002/cncr.29899.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalExercise TherapyFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm InvasivenessNeoplasm StagingPhysical FitnessQuality of LifeRadiotherapy, AdjuvantReference ValuesSurvival AnalysisTreatment OutcomeUnited StatesConceptsMetastatic breast cancerEarly-stage breast cancerExercise interventionBreast cancerPhysical functioningLife Questionnaire-Core 30 questionnaireModerate-intensity aerobic exercisePhysical Activity Recall interviewModerate-intensity exercise interventionAdvanced breast cancerPhysical activity interventionsTime of enrollmentWait-list control groupQuality of lifeMetastatic diseaseCancer QualityMedian ageIntervention armMedian timeActivity interventionsAerobic exerciseWeekly exerciseTreadmill testFunctional capacityNonsignificant increase
2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Research And Treatment 2015, 151: 589-596. PMID: 25981899, PMCID: PMC5057177, DOI: 10.1007/s10549-015-3426-z.Peer-Reviewed Original ResearchConceptsChemotherapy-related amenorrheaChemotherapy initiationMenopausal symptomsBreast cancerAdjuvant breast cancer therapyEarly-stage breast cancerNode-negative HER2Weeks of paclitaxelStage breast cancerLast menstrual periodBreast cancer therapyAdjuvant paclitaxelAmenorrhea ratesAPT trialEligible patientsEvaluable populationPremenopausal womenAdjuvant studiesTrastuzumab monotherapyMedian timeMenstrual periodCancer regimensAmenorrheaTrastuzumabMonths
2014
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal Of Clinical Oncology 2014, 32: 3744-3752. PMID: 25332249, PMCID: PMC4226805, DOI: 10.1200/jco.2014.55.5730.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptorOverall survivalBreast cancerEpidermal growth factor receptorGrowth factor receptorNCCTG N9831NSABP BEarly-Stage Human Epidermal Growth Factor ReceptorHER2-positive operable breast cancerNational Surgical Adjuvant BreastLarge adjuvant trialsOperable breast cancerAddition of trastuzumabAnti-HER2 agentsFactor receptorSurvival end pointsBreast cancer resultsDFS ratesOverall DFSAdjuvant BreastAdjuvant chemotherapyAdjuvant trialsOS ratesMedian timePatient subgroups
2013
Quality of life and psychosocial distress in young women with advanced breast cancer.
Seah D, Gelber S, Ruddy K, Tamimi R, Schapira L, Come S, Meyer M, Larsen B, Winer E, Partridge A. Quality of life and psychosocial distress in young women with advanced breast cancer. Journal Of Clinical Oncology 2013, 31: e20508-e20508. DOI: 10.1200/jco.2013.31.15_suppl.e20508.Peer-Reviewed Original ResearchAdvanced breast cancerQuality of lifePsychosocial distressBreast cancerYoung womenBodily painSF-36 subscale scoresBaseline surveyLongitudinal multi-centre studyMedical chart dataMental health scoresMulti-center studySocial functioningABC diagnosisABC patientsClinical factorsMedian ageMedian timeClinical variablesRole limitationsGeneral healthDepressed womenHealth scoresGeneral populationLogistic regressionLong‐Term Risk Perceptions of Women With Ductal Carcinoma In Situ
Ruddy KJ, Meyer ME, Giobbie‐Hurder A, Emmons KM, Weeks JC, Winer EP, Partridge AH. Long‐Term Risk Perceptions of Women With Ductal Carcinoma In Situ. The Oncologist 2013, 18: 362-368. PMID: 23568001, PMCID: PMC3639521, DOI: 10.1634/theoncologist.2012-0376.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerDuctal carcinomaLifetime riskFuture breast cancer eventsHistory of DCISBreast cancer eventsTime of diagnosisLong-term followLongitudinal cohort studyFuture breast cancerWorse financial statusCohort studyMedian timeCancer eventsDCISOnly predictorModerate riskMultivariate modelCancerWomenDiagnosisRisk perceptionCarcinomaRecurrence
2012
Time to diagnosis and breast cancer stage by race/ethnicity
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Research And Treatment 2012, 136: 813-821. PMID: 23099438, PMCID: PMC3513497, DOI: 10.1007/s10549-012-2304-1.Peer-Reviewed Original ResearchConceptsRace/ethnicityLate-stage tumorsBreast cancerMedian timeNon-Hispanic Asian/Pacific Islander womenStage III/IV breast cancerAbnormal mammogramsNational Comprehensive Cancer Network centersAsian/Pacific Islander womenBreast cancer stageNon-Hispanic blacksPacific Islander womenNon-Hispanic whitesBreast cancer diagnosisAJCC criteriaHigher proportionSymptomatic womenCancer stageStage IStage IIIInitial signsRandomized trial of a physical activity intervention in patients with metastatic breast cancer.
Ligibel J, Giobbie-Hurder A, Shockro L, Campbell N, Partridge A, Tolaney S, Lin N, Winer E. Randomized trial of a physical activity intervention in patients with metastatic breast cancer. Journal Of Clinical Oncology 2012, 30: 9084-9084. DOI: 10.1200/jco.2012.30.15_suppl.9084.Peer-Reviewed Original ResearchMetastatic breast cancerDiagnosis of MBCPhysical activity interventionsPA interventionsBreast cancerActivity interventionsModerate-intensity PA interventionUsual care control groupEarly-stage breast cancerPhysical Activity Recall interviewFunctional measuresActive brain metastasesEORTC QLQ CCare control groupBruce treadmill testQuality of lifeECOG 0Brain metastasesHormonal therapyQLQ CBiologic therapyMedian ageIntervention armMedian timeTreadmill time
2011
PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery.
Rosenberg S, Tamimi R, Gelber S, Kereakoglow S, Borges V, Come S, Schapira L, Winer E, Partridge A. PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery. Cancer Research 2011, 71: pd04-05-pd04-05. DOI: 10.1158/0008-5472.sabcs11-pd04-05.Peer-Reviewed Original ResearchCare scoresBreast cancerYoung womenConcurrent treatmentTreatment groupsMulti-center prospective cohort studyHormone treatmentYoung breast cancer patientsBody image issuesMean CARE scoreBody imageProspective cohort studyBreast cancer patientsImpact of chemotherapyStage of diseaseTreatment-associated differencesImpact of treatmentHormonal therapyCohort studyHormone therapyRadical surgerySurgical groupMedian ageMedian timeUnadjusted analyses
2009
Presentation of breast cancer in young women
Ruddy K, Gelber S, Tamimi R, Schapira L, Come S, Kereakoglow S, Lin N, Winer E, Partridge A. Presentation of breast cancer in young women. Journal Of Clinical Oncology 2009, 27: 6608-6608. DOI: 10.1200/jco.2009.27.15_suppl.6608.Peer-Reviewed Original ResearchSigns/symptomsMedical attentionBreast cancerYoung womenDiagnostic delayMedian timeExact testInitial signsProspective multicenter cohort studyInitial signs/symptomsLarge modern cohortPotential diagnostic delayMulticenter cohort studyClinical breast examBreast Self-ExamPredictors of delayFisher's exact testCohort studyModern cohortMedian agePatient factorsPoor outcomePrognostic implicationsSystemic symptomsBreast examTolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer
Come S, Parker L, Wulf G, Kuter I, Ryan P, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer E. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. Journal Of Clinical Oncology 2009, 27: 1050-1050. DOI: 10.1200/jco.2009.27.15_suppl.1050.Peer-Reviewed Original ResearchClinical benefit rateStable diseasePartial responseComplete responseEstrogen receptorEndocrine therapyMedian timeBreast cancerEvaluable metastatic breast cancerFirst-line metastatic settingInjection site discomfortAdjuvant endocrine therapyAdjuvant endocrine treatmentPhase II studyTreatment-related toxicityMetastatic breast cancerAdvanced diseaseEndocrine treatmentMetastatic settingPostmenopausal patientsPrimary endpointRECIST criteriaVisceral metastasesII studyPostmenopausal women
2008
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research And Treatment 2008, 115: 115-121. PMID: 18496750, DOI: 10.1007/s10549-008-0055-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineCohort StudiesDeoxycytidineDisease ProgressionErbB ReceptorsErlotinib HydrochlorideFemaleFluorouracilHumansMiddle AgedNeoplasm MetastasisProtein Kinase InhibitorsQuinazolinesTaxoidsConceptsAdvanced breast cancerSafety of erlotinibBreast cancerCohort 1 patientsCohort 2 patientsResults One patientCommon adverse eventsPhase II studyAdvanced stage diseaseMetastatic breast cancerBreast cancer patientsPrimary endpointSecondary endpointsAdverse eventsII studyPartial responseMedian timePredictive factorsCancer patientsErlotinib treatmentCohort 2Cohort 1Design MulticenterOne patientDry skinFertility and Menopausal Outcomes in Young Breast Cancer Survivors
Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, Przypyszny M, Winer EP. Fertility and Menopausal Outcomes in Young Breast Cancer Survivors. Clinical Breast Cancer 2008, 8: 65-69. PMID: 18501060, DOI: 10.3816/cbc.2008.n.004.Peer-Reviewed Original ResearchConceptsYoung breast cancer survivorsBreast cancer survivorsCancer survivorsBreast cancerYoung womenFuture pregnanciesEarly-stage breast cancerOvarian suppression therapyBreast cancer treatmentMost young womenBreast cancer diagnosisSuppression therapyMedian timeLive birthsFertility issuesCancer treatmentDiagnosisCancer diagnosisWomenCancerSurvivorsChemotherapyPregnancyOutcomesInternational advocacy groups
2007
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert‐Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007, 110: 965-972. PMID: 17614302, DOI: 10.1002/cncr.22885.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlopeciaAnemiaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsConstipationDisease ProgressionDrug Administration ScheduleFatigueFemaleHumansKaplan-Meier EstimateMiddle AgedNauseaNeoplasm MetastasisPaclitaxelProspective StudiesReceptor, ErbB-2TrastuzumabTreatment OutcomeVinblastineVinorelbineConceptsMetastatic breast cancerBreast cancerTrastuzumab armEpisodes of cardiotoxicityFirst-line therapyDermatologic toxicitiesEvaluable patientsPrior chemotherapyVinorelbine therapyAdvanced diseaseChemotherapy regimenEligible patientsGastrointestinal toxicityPoor accrualTaxane chemotherapyTaxane therapyMore anemiaMedian timeTrastuzumab treatmentFluid retentionDisease progressionChemotherapy agentsTreatment decisionsVinorelbineSide effects